KALA BIO Eyes Pharma R&D Spend With Secure AI Licensing Model

KALA BIO, Inc. (NASDAQ: KALA) shares rose Wednesday after the biotechnology company unveiled a strategic initiative to build an on-premises artificial intelligence infrastructure platform for the biotech sector.

The company also entered a platform development and exclusive license agreement with 2624465 Ontario Inc., operating as Younet AI, for its proprietary AI research platform, Researgency. The deal grants KALA exclusive worldwide rights to deploy the platform in biotechnology during an initial 12-month term, with options to renew.

Researgency Platform And Licensing Model

Researgency runs entirely within a client's own infrastructure, allowing biotech and pharmaceutical companies to analyze proprietary biological data using AI without transferring sensitive datasets to external cloud platforms.

KALA said most AI drug discovery platforms rely on centralized cloud models that require companies to upload proprietary data to third-party environments—an approach that can deter biotech firms seeking to protect biological datasets, trade secrets and regulatory-sensitive information.

AI-driven drug discovery is expanding within a pharmaceutical R&D market exceeding $167 billion, but adoption remains limited, particularly among smaller biotech firms lacking secure AI infrastructure.

KALA plans to first deploy Researgency internally using its MSC-S platform datasets and KPI-012 clinical program. Following validation, the company intends to license the platform to biotech and pharmaceutical companies through a recurring subscription model.

Chief Executive Officer Avi Minkowitz said the strategy is designed to bring institutional-grade AI capabilities directly to biotech companies while allowing them to retain full control of their intellectual property.

Technical Analysis

The stock is currently trading 2.5% above its 20-day simple moving average (SMA) and is 3.1% below its 100-day SMA, indicating some short-term strength but potential resistance in the longer term.

Over the past 12 months, shares have decreased significantly, reflecting challenges faced by the company, and are currently positioned closer to their 52-week lows than highs.

The RSI is at 50.00, which is considered neutral territory, suggesting that the stock is neither overbought nor oversold at this time. Meanwhile, MACD is at 0.10, below its signal line at 0.15, indicating some bearish pressure on the stock.

The combination of neutral RSI and bearish MACD suggests mixed momentum, indicating that traders should watch for potential shifts in market sentiment.

• Key Resistance: 50 cents
• Key Support: 35 cents

KALA Price Action: Kala Bio shares were up 5.51% at $0.37 at the time of publication on Wednesday.

Photo by PeopleImages.com – Yuri A via Shutterstock